822 A1A NORTH, PONTE VEDRA, FL
Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CFO Appointment - John P. Sharp Named Interim Chief Financial Officer
To File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
CFO Departure - Matthew Szot Transitioning; Quang Pham Named Interim CFO
Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Warrant Inducement Agreement - Cadrenal Therapeutics Enters New Deal
Financial Results, Press Release
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement